Firefly Neuroscience, Inc., an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, announced the closing of up to $12.4 million consisting of $2.4 million up front in the form of senior secured convertible notes at $3.00 per share, subject to adjustment, and an equity line of credit (the “ELOC”) for up to $10 million. The proceeds from these financings will be used for growth, commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) technology, and general working capital purposes.
“The closing of this financing strengthens our balance sheet and provides us the financial flexibility to continue to execute on our growth strategy,” said Greg Lipschitz, Executive Chairman of Firefly. “The additional working capital will allow us to accelerate two strategic commercialization pathways for our BNA technology. Through partnering with neuroscience pharmaceutical companies and by supporting US neurologists and psychiatrists in the diagnosis and optimization of patient care, we are driven to improve outcomes for people suffering from brain health illnesses.”
Also Read: Galera Therapeutics Acquires Nova Pharmaceuticals
Firefly is an Artificial Intelligence company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Source: GlobeNewsWire